PRA Health Sciences (PRAH) Tops Q2 EPS by 4c; FY19 EPS Mid-Point Guidance Above Consensus, FY19 Revenue Mid-Point Below Consensus
Tweet Send to a Friend
PRA Health Sciences (NASDAQ: PRAH) reported Q2 EPS of $1.22, $0.04 better than the analyst estimate of $1.18. Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
